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1. Introduction 
Worldwide, lung carcinoma (LC) is the commonest and deadliest form of cancer in men and 
women, exceeding the mortality of prostate, breast, and colorectal cancers combined (Jemal 
et al., 2009). Irrespective of histologic subtype, more than 90% of all LC is strongly 
associated with cigarette smoking (Alavanja et al., 2002), and the risk significantly increases 
with the number of cigarettes smoked per day, degree of inhalation, age at initiation, and 
life-long cumulative exposure (Tyczynski et al., 2003). Although survival at 5-year is less 
than 15%, yet,  there exists no single proven chemopreventive measure reducing the risk of 
LC development, except for cessation of cigarette smoking. 
Histologically, non-small cell LC (NSCLC) and small-cell LC (SCLC) are the two commonest 
types of LC, constituting 85-90% and 10-15% of all cases, respectively (Rosenzweig et al., 
2010). SCLC (previously called oat cell carcinoma) is relatively less common than NSCLC; 
however, because of a more aggressive growth pattern and clinical course, its treatment is 
more challenging. Although there is no significant difference in outcome by histologic 
subtype, the World Health Organization classification subdivides SCLC into three cell types; 
pure or classic, variant cell, and mixed (Brambilla et al., 2001). SCLC displays a high 
propensity to metastasize, and usually a remarkable but temporary responsiveness to 
chemotherapy and radiotherapy (RT). Although some may be cured, most patients succumb 
to disease because of rapid development of drug resistance and resultant disease 
progression. Median survival for metastatic SCLC is only 10 months, which is interestingly 
very similar to patients with relatively much more drug resistant NSCLC of similar stage 
(Chute et al., 1997). Despite great improvements in imaging, pathology, genetics, 
chemotherapy, and RT techniques, this did not translate into the clinical outcomes, thus, the 
current overall survival rate for SCLC patients is not different than that was 20 years before 
(Chute et al., 1997). 
This chapter has been designated to focus specifically on treatment of SCLC patients, with 
specific emphasises on the technical basis and outcomes of current RT and concurrent 
chemoradiotherapy (C-CRT). Therefore, readers interested in more comprehensive 
information about the epidemiology, etiology, preventive measures, pathologic and  
genetic basis and surgical treatment of SCLC are referred to excellent reviews available in 
this book. 
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2. Staging 
Management of SCLC begins with the accurate staging of the disease. Historically, using the 
Veteran’s Administration Lung Study Group (VALG) criteria (Zelen, 1973), staging of SCLC 
was simplified to include two stages: limited stage SCLC (LS-SCLC), and extensive stage 
SCLC (ES-SCLC). LS-SCLC is defined as the disease confined to the ipsilateral hemithorax 
which can be safely encompassed within a tolerable single radiation port. Involvement of 
ipsilateral supraclavicular lymph node region is also included in limited-stage disease. In 
contrast; patients with ES-SCLC have disease that is beyond the ipsilateral hemithorax. 
Besides the hematogenous spread, involvement of contralateral supraclavicular lymph node 
region and/or presence of malignant pleural- and/or pericardial effusion are included in 
extensive-stage disease. Only less than one third of SCLC patients present with limited-stage 
disease, while remaining two thirds have extensive-stage disease, and are treated with 
palliative chemotherapy. 
The revised American Joint Committee on Cancer (AJCC) staging system implemented the 
TNM staging for NSCLC, but its use for SCLC was also recommended in sixth and seventh 
editions (Edge, 2010; Greene, 2002). Recent study by Vallieres et al., constituting of 349 
patients with resected SCLC confirmed the utility of TNM-based pathologic staging in terms 
of survival outcomes. But, because of being restricted to only 5% SCLC patients presenting 
with an operable disease at presentation, TNM-based staging has not been routinely 
adopted two tired VALG staging system (LS-SCLC and ES-SCLC) in this group of patients 
(Vallieres et al., 2009). 
3. Prognostic factors 
Despite paramount improvements in imaging and treatment modalities,  prognosis of 
patients with SCLC is still unacceptably poor with median survival ranges of only 15-20 
months for LS-SCLC and 8-13 months for ES-SCLC (Lally et al, 2007). Furthermore, 5-year 
survivors are reported to be only in the respective ranges of 10-13% and 1-2%, emphasizing 
the futility of the condition (Lassen, 1995; Tai, 2003). A number of factors have been assigned 
to carry prognostic importance for patients with SCLC but the most important tumor related 
factor is the VALG stage (LS-SCLC versus ES-SCLC). In LS-SCLC, early stage disease that 
corresponds to TNM stage 1 carries the best prognosis specifically in the absence of elevated 
serum lactate dehydrogenase levels (Byhardt, 1986; Lassen, 1995). Similar to other tumor 
sites, weight loss and poor performance status are significant predictors of unfavorable 
outcome (Paesmans et al., 2000). Likewise, men fare poorer than women (Lally et al, 2007). 
In ES-SCLC, the number of organ sites and site of involvement are also strongly associated 
with prognosis (Albain et al, 1991). Compared to other sites, involvement of bone marrow, 
liver, or central nervous system signify unfavorable disease course. 
Compared to NSCLC, SCLC is more frequently associated with paraneoplastic syndromes 
either via antibody-mediated tissue destruction or via ectopic hormone production (Lally et 
al, 2007). Although, some debate exists, unlike antibody-mediated paraneoplastic 
syndromes, ectopic hormone production is generally accepted as a predictor of poor 
outcome. Favorable prognosis linked to antibody-mediated paraneoplastic syndromes may 
be related with presence of a fully competent immune system, indicating the need for 
exploration of immunotherapy adjunct to standard treatment approaches in this patients 
group.          
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4. Treatment for limited-stage small cell lung carcinoma 
4.1 Chemotherapy 
In LS-NSCLC, chemotherapy trials conducted in the 1970s improved survival from weeks to 
months. Over the following three decades, several studies have shown that combination 
chemotherapy regimens were clearly more efficacious than single agent regimens. Response 
rates of 70%-85%, with complete response of 20%-30%, are encouraging but virtually almost 
every patient relapses (Lally et al, 2007). Results of randomized investigations and meta-
analysis for the most active regimen indicated the superiority of etoposide plus cisplatin 
(EP) combination over the other tested combinations (Fukuoka, 1991; Pujol, 2000; Roth, 1992; 
Sundstrom, 2002). Therefore, the EP combination has become the standard care 
chemotherapy combination in United States and Europe since 1980s. Although cisplatin is 
the backbone of chemotherapy, carboplatin may be substituted for cisplatin in older patients 
or in those with renal insufficiency without an apparent efficacy loss (Okamoto et al., 2005). 
Chemotherapy combinations constituting a variety of newer agents, like irinotecan, have 
been tested in an effort to improve current outcomes in LS-SCLC. However, these agents do 
not appear to be more active than older counterparts. Irinotecan, which was the most 
promising of them, has been tested in three randomized phase 3 trials (Hanna, 2006; Lara, 
2009; Noda, 2002). The first trial by Noda et al. demonstrated the superiority of cisplatin 
plus irinotecan (IP) over the standard EP combination in a Japanese Clinical Oncology 
Group (JCOG) trial (Noda et al., 2002). However, two subsequent trials launched in United 
States could not validate these results (Hanna, 2006; Lara, 2009). In both trials response and 
survival rates in patients treated with investigational IP were found to be equivalent to 
standard EP. The potential benefit of adding a third agent to standard EP has also been 
extensively investigated. Higher response rates at a cost of significantly increased toxicity 
were achieved, with no notable improvement in median survival duration over EP alone 
(Loehrer, 1995; Mavroudis, 2001; Niell, 2005; Pujol, 2001).  
Based on these results, the current standard for the first line chemotherapy in this group of 
patients is 4 to 6 cycles of EP combination, and further treatment with either maintenance 
therapy or four cycles of topotecan following standard EP regimen has not been proved to 
improve outcomes (Schiller, 2001; Sculier, 1998).  
4.2 Thoracic radiotherapy 
Before the introduction of chemotherapy in the 1970s, thoracic radiotherapy (TRT) was the 
mainstay of treatment for LS-SCLC. However, management of LS-SCLC with chemotherapy 
alone results in unacceptable rates of intrathoracic failures, ranging from 75 to90% (Faivre-
Finn et al. 2005). In this setting, integration of TRT to chemotherapy reduces these failures 
up to 30 to 60%. Impact of such a decrease in intrathoracic failures has been extensively 
investigated by two meta-analyses (Pignon, 1992; Warde & Payne, 1992). In the first one, 
Warde and Payne (Warde & Payne, 1992) analyzed 11 randomized studies including 1911 
patients, and reported a significantly longer overall survival with the combination of TRT 
and chemotherapy than with chemotherapy alone, with an absolute benefit of 5.4% at 2-year 
(p<0.001). In the other meta-analysis, Pignon et al. (Pignon et al., 1992) included 13 trials 
consisting of 2103 LS-SCLC patients. Combination of TRT and chemotherapy again resulted 
in an absolute survival advantage of 5.4% at 3-year compared to chemotherapy alone 
(p=0.001). Based on the results of these two meta-analyses combination of TRT and 
chemotherapy became the established standard of care in LS-SCLC. 
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TRT delivered both sequentially and concurrently with chemotherapy has been intensively 
assessed. Although sequential treatment approach has the theoretical benefits by chance of 
irradiating smaller target volumes with resultant reduced toxicity rates, the associated longer 
overall treatment time potentially increases the risk of accelerated tumor repopulation and 
development of treatment-resistant clones. In this context, concurrent use of chemotherapy 
and TRT does not only reduce the risk for accelerated repopulation but also offers a chance for 
better locoregional control by utilizing the radiosensitizing efficacy of chemotherapeutic 
agents. Nevertheless, despite such potential benefits, because of increased risk for higher rates 
of acute toxicity with concurrent chemoradiotherapy, sequential use of chemotherapy and TRT 
may be more feasible in elderly patients or those with larger tumors.  
Data on the optimum radiotherapy dose and fractionation come mostly from retrospective 
and phase 2 prospective studies. The results from non-randomized studies indicate a 
notable increase in local control when the dose of TRT is increased from 35 to 40 Gy, and a 
slightly further gain with 50 Gy. Laboratory studies have suggested that typical SCLC cell 
lines have radiation survival curves with little shoulders indicating that accelerated 
fractionation schemes would, therefore, be advantageous (van Meerbeeck et al., 2011). In 
1999, two different cooperative groups randomized patients to once-a-day versus twice-a-
day TRT with concurrent chemotherapy, as depicted in Table 1 (Bonner, 1999; Turrisi, 1999). 
In the study by Bonner et al., authors reported the North Central Cancer Treatment Group 
(NCCTG) experience, and concluded that there was no difference in survival with twice-
daily TRT versus once daily counterpart (Bonner et al., 1999). However, this study has been 
criticized because of using split-course RT schedule which is currently an established factor 
to increase the chance for accelerated repopulation, and therefore, affect treatment outcomes 
in an unfavorable fashion. In the landmark study by Turissi et al. (Int-0096), authors 
reported the long-term outcomes of 358 patients enrolled onto the cooperative group study 
of Eastern Cooperative Oncology Group/ Radiation Therapy Oncology Group 
(ECOG/RTOG) with the diagnosis of LS-SCLC. Results of this study demonstrated that 
twice-daily 45 Gy (1.5 Gy BID) and concurrent CRT was significantly superior over 
conventionally fractionated TRT scheme (Turrisi et al., 1999). Based on the results of this 
latter study, the current standard of care for medically fit LS-SCLC became the 45 Gy (1.5 Gy 
BID) TRT and concurrent EP. Nonetheless, because of the higher frequency of dose limiting 
≥ Grade 3 esophagitis in twice-daily TRT scheme, 54 Gy (1.8 Gy per fraction) in 30 days and 
concurrent EP is also a common and acceptable treatment scheme. 
Carcinoma and Leukemia Group B (CALGB) conducted two phase 2 trials to investigate the 
potential benefit of a higher dose of 70 Gy given in 35 fractions within 7 weeks (Bogart, 2004; 
Miller, 2007). In the first study, median survival, 2-year survival rate, and ≥ Grade 3 
esophagitis rate were 22 months, 48%, and 21%, respectively (Bogart et al., 2004). In the 
second study respective rates were 20 months, 35%, and 30% (Miller et al., 2007). Based on 
the promising results of these two trials, two ongoing randomized Phase 3 trials were 
conducted to compare standard Turissi protocol with escalated doses of conventionally 
fractionated TRT. Results of these two landmark trials summarized in Table 2, will address 
the question whether the higher doses delivered by once daily scheme in 7-week, could 
compensate for the longer interval between the initiation of treatment  and the end of TRT, 
in the expense of increased risk for accelerated tumor cell repopulation. 
In treatment of LS-SCLC, another issue of interest is whether TRT should be administered 
early or late during the chemotherapy course. This question has been addressed by a 
number of trials with no firm conclusions (Gregor, 1997; Jeremic, 1997; Murray, 1993; Perry,  
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 ECOG/RTOG P NCCTG P 
Study Arms Chemo + 
TRT 
Chemo + twice 
daily TRT 
 
Chemo + 
TRT 
Chemo + twice 
daily TRT 
 
Number 176 182 - 133 130 - 
Total cycles of CTX  4 4 - 6 6 - 
Cycles of 
concurrent CTX  
2 2 - 2 2 - 
Median survival 
(mo) 
18.6 20.3 
0.04 
21 21 
0.49 2-year survival (%) 42 44 47 45 
3-year survival (%) - - 34 29 
5-year survival (%) 16 26 - - 
≥Grad 3 
Esophagitis 
33 (16%) 67 (32%) <0.001 7 (5.3%) 16 (12.3%) 0.05 
≥Grad 3 Pulmonary 
toxicity 
8 (4%) 14 (5%) 0.97 6 (4.5%) 8 (6.2%) >0.05 
Table 1. Limited-stage small cell lung cancer with daily versus twice-daily TRT 
 
Study CTX Standard arm Experimental arm 
Primary 
endpoint 
Expected 
enrollment 
CONVERT 4xEP 45 Gy/30 fx, 3 
week, BID, 
starting at second 
course 
66 Gy/33 fx, 6.6 
week, once-daily, 
starting at second 
course 
Overall 
survival 
532 
RTOG0538/ 
CALGB30610 
4xEP 45 Gy/30 fx, 3 
week, BID, 
starting at first or 
second course 
A: 70 Gy/35 fx, 7 
week, once-daily 
B: 61.2 Gy/34 fx, 5 
week, BID, 
starting at first 
course     
Overall 
survival 
712 
Table 2. Benchmark ongoing trials of chemoradiotherapy for limited-stage small-cell lung 
carcinoma 
1987; Skarlos, 2001; Takada, 2002; Work, 1997). In the landmark phase 3 ECOG/RTOG trial 
reported by Turissi et al., the shortening of total irradiation period from 5 weeks to 3 weeks 
was associated with an absolute 10% (16% versus 26%) increase in 5-year survival (Turrisi et 
al., 1999). Results of three other trials revealed a significantly superior survival advantage 
for early TRT over late TRT, confirming the findings of intergroup trial (Jeremic, 1997; 
Murray, 1993; Takada, 2002). The impact of timing of TRT relative to chemotherapy has also 
been addressed by various meta-analyses. De Ruysscher and colleagues conducted a meta-
analysis of phase III trials combining TRT and platinum-based chemotherapy, and 
concluded that the most important predictor of 5-year survival was the interim between the 
start of any treatment until the end of RT (SER), with shorter SERs (<30 days) being associated 
with the highest 5-year survival rates (>20%) (De Ruysscher et al., 2006). With a subsequent 
meta-analysis, Pijls-Johannesma and colleagues evaluated the impact of timing of TRT by 
comparing early versus late TRT, by defining early TRT as within 30 days of beginning 
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chemotherapy. In presence of platinum-based chemotherapy, the 2- and 5-year survival rates 
were favoring early TRT, and this difference was significant only if the TRT was administered 
in a treatment period of less than 30 days. In this study, patient compliance was found to be of 
paramount importance, indicating the importance of patient selection in clinical trials (Pijls-
Johannesma et al., 2007). In a relatively older meta-analysis by Fried et al., late TRT was 
defined as beginning 9 weeks after the initiation of chemotherapy or after the completion of 
third cycle of chemotherapy. Similar to other subsequent meta-analyses, this meta-analysis 
also demonstrated a statistically significant benefit of early TRT over late TRT in terms of 2-
year overall survival. On subset analysis of studies that used hyperfractionated TRT, treatment 
with early versus late TRT revealed a survival benefit, but not when once-daily TRT was 
employed. Likewise, the survival benefit for early versus late TRT was observed uniquely in 
studies using platinum-based chemotherapy, which was not notable in studies using non-
platinum-based chemotherapy (Fried et al., 2004). Results of the available studies and meta-
analyses suggested an interaction between TRT and chemotherapy and, accelerated tumor cell 
repopulation was postulated to be triggered by the first dose of any effective cytotoxic agent 
(De Ruysscher et al., 2006). Therefore, to obtain the highest chance for local/regional control, 
the last clonogenic tumor cell should be killed by the end of TRT (van Meerbeeck et al., 2011). 
Hence, long-term survival decreases with increasing time between the initiations of any 
treatment and the completion of TRT.  
In summary, current evidence recommends the early administration of 45 Gy (1.5 Gy, BID) 
with concurrent EP at systemic doses in medically fit LS-SCLC patients.          
4.4 Radiotherapy techniques and treatment fields 
Treatment for lung tumors, including SCLC, is complex. In order to ensure safe and effective 
RT, several issues must be considered: (a) accurate target volume delineation; (b) proximity 
of dose limiting normal structures (lung, spinal cord, esophagus, heart, brachial plexus, and 
liver); (c) anatomic slope of the chest surface; (d) inhomogenities resulting from the  
presence of nonuniform tissues on the way of RT; (e) frequent need for irregular field dose 
calculations; (f) respiratory motion of the targeted tumor and normal tissues such as lung, 
heart and liver, depending on the location of the primary tumor and involved lymphatic 
region(s). 
The ultimate goal of any RT application is to deliver the prescribed dose homogenously (not 
cooler than 95% and not hotter than 107%) to the planned target volume and keep the dose to 
non-tumorous normal tissues as minimum as possible respecting their tissue architecture 
(serial versus parallel) and their radiation tolerance limits. In this setting, with the aid of 
imaging with anatomic computerized tomography (CT), functional 18-F-fluorodeoxyglucose 
positron emission tomography (PET), preferably fusion of both) and the use of 3–dimensional 
conformal RT, and novel 4-dimensional image-guided RT (IGRT), it is easier than before to 
achieve these goals. Additionally, the dose-volume histograms (DVH) created for each patient 
makes it possible to anticipate the potential early and late toxicity risks based on the organ of 
interest measures and, therefore, modify the treatment plans as necessitated. 
There is considerable debate on the size of the RT portals of SCLC. Historically, RT portals 
were large, encompassing the primary tumor as well as both hilar, entire mediastinal and 
both supraclavicular lymph node regions with generous margins. This was believed to be 
necessary to ensure adequate coverage of gross disease prior to the routine use of CT- based 
RT planning. Although such large field plans may guarantee the irradiation of target 
volumes, they are also associated with increased acute and late toxicity rates and unplanned 
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treatment delays, which may negatively impact both quality of life measures and 
local/regional control rates and related survival outcomes. This issue is specifically argued 
when TRT is delayed after the completion of induction chemotherapy. Although some 
authors advocate generous portals encompassing the pre-chemotherapy volumes as stated 
above, others argue that only limited portals encompassing the pre-chemotherapy primary 
tumor and high-risk nodal areas with a 1-cm margin are adequate, since effective 
chemotherapy has the theoretical chance to cope with subclinical or microscopic disease 
eliminating the need for generous portals. This latter approach has the additional potential 
for decreased treatment related toxicity specifically when TRT is administered concurrently 
with chemotherapy. Treatment directed at pre- versus post-chemotherapy volumes is also 
an ongoing issue of conflict. The unique randomized trial that addressed this issue is the one 
conducted by the South West Oncology Group (SWOG). In this study, patients achieving a 
partial response after chemotherapy were randomized to pre- versus post-chemotherapy 
volume irradiation arms. Outcomes of this benchmark study did not indicate any 
superiority for pre-chemotherapy volume irradiation arm over post-chemotherapy 
irradiation counterpart, in terms of neither local/regional nor survival rates (Kies et al., 
1987). This issue has latter been investigated by Liengswangwong et al. in a retrospective 
analysis. The authors were unable to find a benefit favoring pre-chemotherapy large-field 
TRT over post-chemotherapy limited-field TRT (Liengswangwong et al., 1994).  
In NSCLC, elective irradiation of hilar and/or mediastinal lymphatic regions has gradually 
been replaced by treatment limited to nodes identified by CT or FDG –PET as being 
involved. For SCLC, evidence is scarce to support this approach. In a prospective study by 
De Ruysscher et al., authors limited the RT fields to only CT-positive mediastinal lymph 
nodes in a cohort of 27 patients with LS-SCLC. The authors reported an isolated regional 
recurrence rate of 11%, which was higher than similar studies using elective mediastinal 
irradiation. However, because of small sample size, no definitive conclusions can be drawn 
from this study (De Ruysscher et al., 2006). In a larger phase 2 study including 60 LS-SCLC 
patients, van Loon et al., irradiated only the lymph nodes that appeared to be involved on 
FDG-PET, and reported an isolated nodal failure rate of 3%, which awaits to be confirmed 
by further studies with larger cohorts (van Loon et al., 2010). A typical 3-D conformal RT 
plan used in our institution and associated DVH is shown in Figure 1. 
4.5 Prophylactic cranial irradiation 
Approximately 10-14% of SCLC patients have detectable brain metastases (BM) at the time 
of initial diagnosis (Hardy et al., 1990). During the course of disease, the incidence of BM 
increases up to more than 50%, which is far beyond in postmortem examinations (Hirsch, 
1983; Nicholson, 2002). The incidence of BM is directly proportional with the survival time, 
indicating a potential for further increase with implementation of more effective treatment 
protocols (Komaki, 1981; van Oosterhout, 1996). Compared to patients with LS-SCLC, the 
risk for BM occurrence is higher for patients with ES-SCLC reaching 69% at 2- years of 
diagnosis (van Oosterhout, 1996; Yang GY & Matthews, 2000).   
Impact of BM on socioeconomic issues and quality of life is significantly worse than the 
impact of failure at other metastatic sites. Patients with BM are often obliged to spend 
significant time hospitalized, and suffer loss of independence (Felletti et al., 1985). Despite 
cranial irradiation and/or chemotherapy, the treatment of clinically established BM is 
partially satisfactory with intracranial disease control rates of about 50% and overall 
survival of 4 to 6 months (Carmichael, 1988; Lucas, 1986; Postmus, 1989). 
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Fig. 1. An example of typical 3-D conformal RT plan and associated DVH. 
Several randomized trials have been conducted to investigate the utility of prophylactic 
cranial irradiation (PCI) in prevention of BM development in patients with LS-SCLC. 
Logically, in patients with extracranial disease under control, PCI may eliminate the 
intracranial microscopic tumor cell deposits with relatively low radiation doses and, 
therefore, may increase the long-term survival. Results of two randomized controlled trials 
from France (PCI85) and United Kingdom (UK02) demonstrated a trend for better survival 
with PCI but neither could reach statistical significance (Arriagada, 1995; Gregor, 1997). Up 
till now, no individual randomized trial has conclusively demonstrated a survival benefit 
for PCI, which may be related with their deficiency in provision of sufficient power to detect 
moderate differences in survival. 
To conduct a meta-analysis of trials using PCI and to make recommendations for clinical 
practice, the PCI Overview Collaborative Group was established. The meta-analysis reported 
by Auperin et al. in 1999 included individual data from patients enrolled on seven prospective 
randomized PCI trials. Trials eligible in the meta-analysis were limited to those, in which 
patients had been treated with systemic chemotherapy with/without TRT to a complete 
clinical response, and no known BM. PCI treatments were generally between 24 to 40 Gy, 
administered in 2-3 Gy per day. Results of this meta-analysis, for the first time, demonstrated a 
statistically significant survival advantage favoring PCI over non-PCI arm. The relative risk for 
death in the treatment group, as compared to control group, was 0.84 (95 CI, 0.73-0.97; P= 
0.01), which corresponds to a 5.4% higher rate of survival at 3 years (20.7% versus 15.3%), and 
the survival advantage persisted over time. As a percent gain over control, this represents a 
35% increase in the proportion of surviving patients. There was also significant difference in 
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disease-free survival at 3 years from 13.3% in the non-PCI group to 22.1% in the PCI group 
(p<0.0001). PCI was additionally associated with a 25.3% absolute decrease in the cumulative 
incidence of BM at 3 years, from 58.6% to 33.3% (p<0.0001) (Auperin et al., 1999). Results of 
this comprehensive meta-analysis have recently been confirmed by the review of data from 
Surveillance Epidemiology and End Results (SEER) reported by Patel et al. Of 7995 LS-SCLC 
patients included, 670 received PCI. Better overall and cause-specific survival were observed 
in patients treated with PCI, and corresponding 2- and 5-year survival rates were 23% and 11% 
without PCI and 425% and 19% with PCI (Patel et al., 2009).  
Based on the results of meta-analysis by Auperin et al., PCI became the standard of care in 
patients with LS-SCLC demonstrating complete response following systemic and/or 
local/regional treatment (Auperin et al., 1999). However, an important concern about the use 
of PCI is the need for determination of an established non-toxic but effective fractionation 
scheme and total dose. Available data have shown that lower doses of PCI may be less 
effective in preventing CNS failures (Auperin, 1999; Gregor, 1997). Recently, Le Pechoux et al. 
published the results of benchmark international PCI trial evaluating radiation dose for PCI in 
LS-SCLC. The study randomized 720 LS-SCLC patients from 157 centers to one of two PCI 
arms: Arm-1 included patients receiving standard-dose PCI to 25 Gy in 2.5 Gy per fraction, 
and Arm 2 included patients receiving higher dose PCI to 36 Gy delivered in 2 Gy once daily 
or 1.5 Gy twice daily. No significant difference of BM incidence was reported between two 
study arms, but there was a significantly higher rate of cancer-related mortality in the higher 
dose arm as a result of unexplained finding of more deaths from extracranial disease 
progression (Le Pechoux et al., 2009). Based on the results of this study, 25 Gy delivered at 2.5 
Gy per fraction per day remains the standard of care for PCI in LS-SCLC patients.     
5. Treatment for extensive-stage small cell lung carcinoma 
5.1 Radiotherapy 
Combination chemotherapy is the mainstay in the management of ES-SCLC, but as 
intrathoracic disease control may be a significant challenge to overcome in a significant 
proportion of patients, role of consolidative TRT has been addressed in several trials. 
Jeremic et al. randomized patients with ES-SCLC, who responded completely at 
extrathoracic sites and at least partially at thorax, to consolidation TRT versus observation 
arms after 3 cycles of systemic chemotherapy. In experimental arm, TRT was administered 
in an accelerated hyperfractionated scheme of 54 Gy given in 1.5 Gy twice daily fractions 
concurrently with EP chemotherapy. The median and a 5-year overall survival in the TRT 
arm and no TRT arm were 17 versus 11 month and 9.1% versus 3.7%, respectively (Jeremic 
et al, 1999). However, the results of ongoing studies addressing the question of TRT both in 
Netherlands and in Canada should be awaited before its routine recommendation for 
patients with ES-SCLC.  
5.2 Prophylactic cranial irradiation 
Although the beneficial effects of PCI on prevention of BM occurrence and on augmentation 
of overall and disease-free survival have been well established in LS-SCLC patients, this 
issue had remained to be answered in ES-SCLC until the publication of the results of recent 
EORTC trial. In this benchmark study, patients with ES-SCLC who had a response to 
chemotherapy were randomized to PCI versus observation arms. The cumulative risk of 
symptomatic BM at 1-year and the 1-year survival rate were 14.6% versus 40.4% (p<0.001), 
www.intechopen.com
 Lung Diseases – Selected State of the Art Reviews 
 
248 
and 27.1% versus 13.3% (p=0.003), both favoring the PCI arm (Slotman et al., 2007). 
Following this study, similar to LS-SCLC, PCI became the standard of care in ES-SCLC 
patients except for those experience disease progression during chemotherapy.    
6. Treatment related toxicity 
Acute side effects of CRT often begin during the second or third weeks of treatment. 
Cessation of the tobacco abuse should be the first step in the management of SCLC patients 
to increase the efficacy of intended CRT as well as to decrease the incidence and severity of 
the treatment related side effects. Dermatitis may be seen but severe cases are rare. 
Prevention of trauma is the key for prevention of severe and difficult to treat dermatitis 
development. Aloe vera gel and perfume-free ointments can be safely used in mild to 
moderate dermatitis. Acute esophagitis is usually the dose limiting toxicity of mediastinal 
irradiation, which rarely progress to severe late esophagitis. In patients with mild to 
moderate swallowing difficulty, semisolid nutrition and liquid form analgesics may be 
beneficial. Although confirmation with randomized controlled Phase 3 trials are needed, 
based on the results of two recent retrospective series by Algara et al. and Topkan et al., 
prophylactic use of glutamine may be beneficial in preventing and reducing the severity of 
acute esophagitis (Algara, 2007; Topkan, 2009). Nonproductive dry cough may be seen if 
trachea and/or major bronchi is/are involved in the high dose radiation portals. 
After the completion of TRT, radiation pneumonitis (RP) may be seen at 2 to 4 weeks. RP is a 
form of radiation-induced lung disease, mimicking bacterial pneumonia. Symptoms usually 
include non-productive dry cough, dyspnea, chest pain, palpitations, malaise, and occasionally 
fever. Rales can be noted on auscultation. Plain X-rays and CT are beneficial in demonstrating 
the extent of perivascular haziness and alveolar filling densities primarily within the radiation 
portal. Treatment of RP includes use of 60 mg/day prednisone for two weeks followed by 
gradual tapering at following 3 to 12 weeks. There is no evidence supporting the use of 
prophylactic use of glucocorticoids or antibiotics in preventing or reducing the severity of RP.  
Late toxicities involve chronic esophagitis, pericarditis, myocarditis, pancarditis, spinal cord 
injury, radiation induced lung fibrosis, and secondary cancers. Incidence and severity of all 
these late toxicities depend on the total dose and dose per fraction, fractionation scheme, 
interim between subsequent fractions, volume of non-target organ exposed to specified 
doses of RT, and concurrent use of chemotherapy. Currently, excluding the symptomatic 
management measures, the best treatment method is prevention of toxicity in the presence 
of agents with at best limited healing efficacy. To achieve this, tolerance doses must be 
strictly respected. Specific for radiation-induced lung fibrosis, which may potentially be 
fatal, a recent study demonstrated promising efficacy of pentoxyfilline and alpha-tocopherol 
combination in reduction of fibrotic lung area up to 50% at median 24 months of drug use. 
At long-term, potential neurocognitive toxicity of PCI is of great concern, since sequalae like 
severe memory loss, intellectual impairment or even dementia, ataxia, or seizures have been 
reported in retrospective studies with small size and questionable methodology. For 
example, neurocognitive assessments prior to chemotherapy and/or PCI are lacking despite 
the fact that almost 50% of SCLC patients have neurologic and neurocognitive impairments 
prior to onset of PCI (Arriagada, 1995; Gregor, 1997; Grosshans, 2008; Komaki, 1995). 
Neurocognitive impairment risk has been reported to strongly associate with daily fraction 
sizes of >3 Gy (Paumier & A Le Péchoux, 2010). In one study, Shaw et al. found that the risk 
for neurocognitive impairment following PCI was 2% and 10% at 2- and 5-year follow-ups, 
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respectively. Furthermore, the authors reported that all toxicities were seen with regimens 
using daily fraction sizes of >3 Gy (Shaw et al., 1994). Notably, two randomized studies with 
neurocognitive assessments in patients randomized to PCI versus non-PCI did not 
demonstrate any deterioration in neurologic functions at 30 months, and quality of life 
measures at baseline, at 6 and 12 months (Arriagada, 1995; Gregor, 1997). However, these 
findings do not mean that PCI has no potential toxicity and should be administered to every 
patient with the diagnosis SCLC, rather they impact the importance of patient selection 
based on neurocognitive tests for safer PCI applications.  
7. Treatment algorithm for LS-SCLC and ES-SCLC 
Our current instutitional treatment algorithm for LS-SCLC and ES-SCLC patients is as 
depicted in Figure 2. 
 
 
Fig. 2. Management Algorithm for LS-SCLC and ES-SCLC 
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8. Conclusion 
Significant progress has been made in diagnosis and treatment of SCLC in the last 25 years, 
but, with an overall median survival time of 18 to 20 months, even in patients with limited-
stage disease, it is still not possible to consider SCLC in the category of curable cancers. 
Despite this disappointing figure, mandating further research on this highly fatal disease, all 
improvements in LS-SCLC have been achieved by concurrent use chemotherapy and TRT 
(as early as possible), chemotherapy and PCI. For medically fit patients with ES-SCLC, 
combination chemotherapy followed by PCI (in non-progressive cases) is the standard of 
care, and further consolidation with TRT is currently under investigation. It is of paramount 
importance that patients with ES-SCLC be given the chance to participate in future trials for 
identification of a new and effective treatment combination, which may potentially offer a 
longer survival.    
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